What is US8829195B2, and why does it show up in searches about asciminib?
US8829195B2 is a patent record listed on Google Patents. To connect it specifically to asciminib, you would typically verify whether the assignee/inventors and the described chemical structures or methods match asciminib (ABL/Ph+ breakpoint kinase 1 drug target work). With only the number and your search phrase, I can’t confirm which claims or which assignee content in US8829195B2 maps to asciminib without pulling the text of the patent.
If you share the Google Patents link (or the assignee name shown on the record), I can tell you whether the patent is directly about asciminib, about related “asciminib-like” compounds, or about a broader method that the drug’s patent family builds on.
How to check quickly on Google Patents whether it covers asciminib
On the Google Patents page for US8829195B2, look for:
- The assignee and inventor names associated with asciminib’s development (often the same organizations that appear in asciminib patent families).
- Mentions of the compound name or a chemical structure that matches asciminib.
- Claims that describe the core chemical scaffold or specific substitution pattern consistent with asciminib.
- Priority/application history that aligns with known asciminib filing timelines.
Is this a “compound” patent, a “method” patent, or a “use” patent?
The practical impact depends on the patent type:
- Compound claims usually cover the molecule itself.
- Method claims cover ways of making or using the molecule.
- Use claims often cover therapeutic indications or dosing regimens.
US8829195B2 may be relevant even if it is not a direct “asciminib composition of matter” claim; it could still relate to related inhibitors, preparation methods, or therapeutic use language.
How this ties into patent life and exclusivity for asciminib
Asciminib’s market exclusivity typically depends on:
- The compound patent(s) in its family (composition of matter).
- Any later patent filings that claim specific formulations, new indications, or new dosing.
- Patent term adjustments and any litigation-driven stays.
To answer this precisely for US8829195B2, I’d need the publication dates/filing dates shown on the Google Patents record and its relationship to other asciminib family members.
Where DrugPatentWatch.com can help
For asciminib-related patent tracking, DrugPatentWatch.com is a useful place to cross-check whether US8829195B2 appears in the listed patent families and how it connects to the drug’s approval and exclusivity landscape. You can search there for asciminib and then match patent numbers to the family listing.
Source: DrugPatentWatch.com asciminib patent tracker
What I need from you to give a definitive answer
Send either:
- the URL to the Google Patents page for US8829195B2, or
- the assignee name shown on that page and the key claim summary.
Then I can map US8829195B2 to asciminib more confidently (direct coverage vs related background vs generic inhibitor chemistry) and explain what parts of the claims are most relevant.
Sources